(function(){var loadHandler=window['sl_{B169E353-1691-4AFC-B51D-F07AF60FC333}'];loadHandler&&loadHandler(24, '<div id="spr0_587881d2"><div id="spr1_587881d2" class="kern slide"><img id="img4_587881d2" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_587881d2" class="kern slide"><img id="img0_587881d2" src="data/img3.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_587881d2" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_587881d2" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_587881d2" src="data/img8.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_587881d2" style="left:657.715px;top:499.855px;"><img id="img2_587881d2" src="data/img9.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_587881d2" style="left:-1.875px;top:30.156px;"><div style="width:0px;"><span id="txt0_587881d2" data-width="220.546875" style="left:250.71px;top:5.458px;">OSLER-1 Trial</span></div></div><div id="spr5_587881d2" style="left:6.496px;top:507.023px;"><div style="width:0px;"><span id="txt1_587881d2" class="nokern" data-width="134.982422" style="left:7.2px;top:4.096px;">Koren MJ, et al. AHA 2018. Abstract 118.</span></div></div><div id="spr6_587881d2" style="left:93.916px;top:163.367px;"><img id="img3_587881d2" src="data/img35.png" width="481" height="252" alt="A screenshot of a cell phone  Description automatically generated" style="left:-0.038px;top:-0.13px;"/></div><div id="spr7_587881d2" style="left:14.152px;top:109.232px;"><div style="width:0px;"><span id="txt2_587881d2" data-width="676.328125" style="left:8.651px;top:4.529px;">OSLER-1 trial demonstrates consistent efficacy and safety of evolocumab over 5 years</span></div><div style="width:0px;"><span id="txt3_587881d2" data-width="293.486328" style="left:200.091px;top:28.529px;">in patients with hypercholesterolemia</span></div></div><div id="svg4_587881d2" style="left:261.529px;top:249.912px;"><svg width="237" height="88" viewBox="0 0 237 88"><path fill="#525f83" fill-opacity="0.2" d="M0,0 h236.471 v87.244 h-236.471 Z"/></svg></div><div id="spr8_587881d2" style="left:261.529px;top:249.912px;"><div style="width:0px;"><span id="txt4_587881d2" class="nokern relpos" style="left:7.2px;top:5.464px;"></span><span id="txt5_587881d2" class="relpos" data-width="176.378906" style="left:21.465px;top:4.858px;">Baseline Characteristics:</span></div><div style="width:0px;"><span id="txt6_587881d2" class="nokern relpos" style="left:43.2px;top:26.503px;">─</span><span id="txt7_587881d2" class="relpos" data-width="58.343750" style="left:54.013px;top:26.503px;">48% male</span></div><div style="width:0px;"><span id="txt8_587881d2" class="nokern relpos" style="left:43.2px;top:45.703px;">─</span><span id="txt9_587881d2" class="relpos" data-width="69.289063" style="left:54.013px;top:45.703px;">52% female</span></div><div style="width:0px;"><span id="txt10_587881d2" class="nokern relpos" style="left:43.2px;top:64.903px;">─</span><span id="txt11_587881d2" class="relpos" data-width="158.976563" style="left:54.013px;top:64.903px;">3.6 mmol/L baseline LDL-C</span></div></div><div id="svg5_587881d2" style="left:174.918px;top:418.84px;"><svg width="396" height="66" viewBox="0 0 396 66"><path fill="#525f83" fill-opacity="0.2" d="M0,0 h395.082 v65.433 h-395.082 Z"/></svg></div><div id="spr9_587881d2" style="left:174.918px;top:418.84px;"><div style="width:0px;"><span id="txt12_587881d2" class="nokern relpos" style="left:7.2px;top:5.165px;"></span><span id="txt13_587881d2" class="relpos" data-width="307.078125" style="left:22.38px;top:4.798px;">Discontinued evolocumab due to AEs: 1.4% per year</span></div><div style="width:0px;"><span id="txt14_587881d2" class="nokern relpos" style="left:7.2px;top:24.365px;"></span><span id="txt15_587881d2" class="relpos" data-width="331.156250" style="left:22.38px;top:23.998px;">4 instances of binding antibodies (2 SOC, 2 evolocumab)</span></div><div style="width:0px;"><span id="txt16_587881d2" class="nokern relpos" style="left:7.2px;top:43.565px;"></span><span id="txt17_587881d2" class="relpos" data-width="280.828125" style="left:22.38px;top:43.198px;">No neutralizing antibodies detected over 5 years</span></div></div></div></div>');})();